March 8, 2021 New clinical trial data from Locus Biosciences shows promise in CRISPR-Cas3 technology View link
March 5, 2021 Could this Research Triangle Park company hold a key to fighting drug-resistant bacteria? View link
February 24, 2021 Genetically enhanced antibiotic from RTP firm advances in first-of-its-kind clinical trial View link
February 24, 2021 Locus Biosciences completes first-of-its-kind controlled clinical trial for CRISPR-enhanced bacteriophage therapy View link
December 17, 2020 Gene editing success could turn Triangle startup Locus Biosciences into a billion dollar unicorn View link
November 10, 2020 Locus Biosciences signs contract with CARB-X to advance $14 million precision medicine program to develop crPhage™ product targeting Klebsiella pneumoniae infections More
September 30, 2020 Locus Biosciences signs contract with BARDA to advance $144 million precision medicine program to develop LBP-EC01, a crPhage™ product More
June 29, 2020 The First Controlled Clinical Trial For A CRISPR Enhanced Bacteriophage Therapy View link